Clinical Trial Detail

NCT ID NCT03617328
Title Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma (Mel-65)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Craig L Slingluff, Jr
Indications

melanoma

Therapies

6MHP vaccine + Montanide ISA 51 + Poly ICLC + Varlilumab

6MHP vaccine + Montanide ISA 51 + Poly ICLC

Age Groups: adult senior

No variant requirements are available.